CDMO Company's Shares Surge Over 12 Per Cent in Two Trading Sessions; Here’s Why
CDMO Company's Shares Surge Over 12 Per Cent in Two Trading Sessions; Here’s Why

CDMO Company's Shares Surge Over 12 Per Cent in Two Trading Sessions; Here’s Why

The company's shares surged 10 per cent to hit the upper circuit at Rs 668.10 on the BSE. This marked the second consecutive session of gains for the stock

Manoj Reddy Sama Article rating: 5.0

Under the agreement, Akums will receive an upfront payment of EUR 100 million (Rs 880 crore) to fund product development and secure European regulatory approvals for its oral liquid manufacturing facility.

Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility
Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility

Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility

The inspection, conducted between December 9 and December 17, 2024, resulted in two procedural observations from the US FDA.

Manoj Reddy Sama Article rating: 4.3

The facility in question, Unit-V, is an active pharmaceutical ingredient (API) manufacturing site operated by Apitoria Pharma Private Ltd, a wholly owned subsidiary of Aurobindo Pharma, located in Pashamylaram Village, Telangana.

 

FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit
FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit

FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit

The company reported an impressive over 11 times growth in net profit for the second quarter of FY25, with Profit After Tax (PAT) reaching Rs 17.94 crore compared to Rs 1.61 crore in the same period last year.

Manoj Reddy Sama Article rating: 4.0

Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) significantly increased their holdings in Shilpa Medicare during Q2 of FY25.

Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high
Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high

Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high

The shares of the company saw a spurt in volume by more than 2 times.

Kiran Shroff Article rating: 5.0

The stock gave multibagger returns of 200 per cent in 1 year, 850 per cent in 3 years and a whopping 3,000 per cent in 5 years.

Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!
Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

Pushkar Shinde Article rating: 5.0

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

RSS
1234

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR